AOA Dx
YC S21Denver, US · Founded 2020 · 25 employees · 7 known investors
AOA Dx develops a blood-based liquid biopsy platform using mass spectrometry and machine learning to detect ovarian cancer at early stages through tumor-associated biomarkers in serum. The company serves oncologists and patients in women's health diagnostics.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesHealthcareDiagnosticsWomen's Healthin /aoadx/@AOA_Dx
Founders & leadership· Y Combinator alumni (S21)
Oriana Papin-Zoghbiin𝕏Founder
Alex FisherinFounder/COO
Anna Jeterin𝕏Founder
O
OrianaCEO
A
Alex
A
AnnaChief Regulatory Officer
<
<UNKNOWN>
Investors · 7
In the news
- 💸 Oriana Papin-Zoghbi's AOA Dx Raises $17M to Fund Ovarian Cancer Diagnostic Testfemwealth.substack.com · 2023
- AOA Dx Raises $17M in Fundingfinsmes.com · 2023
- AOA Dx Secures $17M to Advance Its Ovarian Cancer Diagnostic Test | Femtech Insiderfemtechinsider.com · 2023
- Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test – Endpoints Newsendpts.com · 2023
- AOA - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2023
- AOA Dx Reaches Initial Validation of Novel Tumor Gangliosides as Diagnostic Markers for Early Detection of Ovarian Cancer – Femtech Insiderfemtechinsider.com · 2022
- AOA Dx Adds $4.5M in Seed Funding to Develop the Next Generation of Its Ovarian Cancer Detection Technology | Femtech Insiderfemtechinsider.com · 2022
- AOA Dx Closes $7 Million Funding Round To Bring The First Accurate Early Detection Test For Ovarian Cancer To Marketforbes.com · 2022